Turgut Aksoy

Turgut Aksoy

Auto-generated profile, based on publicly available information

Turgut Aksoy

Department of Biochemistry, Faculty of Medicine, Istinye University, İstanbul, Türkiye

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 1997 in Pharmacological Research
Verified
Journal Article
Closed access
MBM. Birincioglu
M. Birincioglu
EOE. Olmez
E. Olmez
TAT. Aksoy
T. Aksoy
AAA. Acet
A. Acet

9 September 2020 in Istanbul Medical Journal
Verified
Journal Article
Closed access
TATurgut Aksoy
Turgut Aksoy
DTDidem Can Trabulus
Didem Can Trabulus
HAHale Aral
Hale Aral
ESErdinç Serin
Erdinç Serin
CTCanan Kelten Talu
Canan Kelten Talu

12 August 2025 in Clinical Oral Investigations
Verified
Journal Article
Closed access
PDF file
CYCansu Can Yasar
Cansu Can Yasar
SASeda Ates
Seda Ates
TATurgut Aksoy
Turgut Aksoy
ATAysegul Yabaci Tak
Aysegul Yabaci Tak
EDEsra Demir
Esra Demir
SGSadiye Gunpinar
Sadiye Gunpinar

25 October 2023 in JOURNAL OF BIOTECHNOLOGY AND STRATEGIC HEALTH RESEARCH
Verified
Journal Article
Open access
PDF file
AAAkın ARSLAN
Akın ARSLAN
ECEmir Cantürk
Emir Cantürk
TATurgut Aksoy
Turgut Aksoy
Objective: The discovery of the protective effects of antioxidant agents on organ functions enabled this system to be tested artificially. The impact of remote ischemic preconditioning (RIPC) on surgical clinical outcomes in patients with congenital heart defects is unclear. This study investigated the early consequences of ischemic preconditioning on cardiac protection. Methods: The study was designed prospectively. Cuffs were applied to one leg of patients in Group 1 (RIPC) after induction of anesthesia in three cycles (5 min inflation followed by 5 min reperfusion) to precondition ischemia-reperfusion. Antioxidant and cardiac marker levels were recorded in blood samples. Results: The patients' surgical median age was 19.1 months (IQR= 3.7- 57.7 months) in Group 1 (RIPC) and 16.7 months (IQR= 7.8- 35.9 months) in Group 2 (Control). The patients' median follow-up period was 58.3 months (IQR= 54.3- 62.1 months) in group 1 and 37.1 months (IQR= 34.8- 41.7 months) in group 2. Hospital mortality was in 7 (10.4%) patients. There was no late mortality. There was a significant difference between the groups in terms of Superoxide Dismutase (SOD) and Malondialdehyde (MDA) levels (p<005). Conclusion: The effects of ischemic preconditioning on cardiac protection have not been proven yet. Especially in congenital cardiac patients, chronic stimuli such as hypoxia and cyanosis or drugs used before surgery may affect the study’s results. Although there is no significant difference in mortality in these patients, a positive effect on the length of hospital stay is promising.